Overview

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.

Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe and has demonstrated the potential to treat multiple severe and life-threatening fibro-inflammatory diseases.

Chemomab has reported positive results from three clinical trials of CM-101 completed to date. A Phase 2 trial in the rare liver disease primary sclerosing cholangitis (PSC) has completed patient enrollment, with topline data expected midyear 2024.

Recent News
Nov 19, 2024

—Clinical Data from Phase 2 SPRING Trial Shows that CM-101 Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis—

Nov 14, 2024

──FDA End-of-Phase 2 Meeting Scheduled in Fourth Quarter 2024 to Discuss the Design of a CM-101 Accelerated Approval Phase 3 Trial in Primary Sclerosing Cholangitis (PSC)── ──Cash...

Oct 30, 2024

TEL AVIV, Israel — October 30, 2024 — Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics...

Oct 15, 2024

TEL AVIV, Israel ─ October 15, 2024 ─ Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

All News

Stock Info
NASDAQCMMB
Events
Friday, November 15, 2024 - Tuesday, November 19, 2024

Date: November 18, 2024, 2:45 pm – 3:00 pm PDT
Format: Late Breaking Oral Presentation: CM-101 improved fibrosis biomarkers in patients with primary sclerosing cholangitis: The Phase 2 SPRING Study
Presenter: Prof. Christopher Bowlus, the Lena Valente Professor and Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine
Information:  https://www.aasld.org/the-liver-meeting

Friday, October 18, 2024
4:25pm - 5:30pm MDT

Session: Industry Updates: Ongoing Clinical Trials in PSC
Speaker: Matt Frankel, MD, Chemomab Chief Medical Officer
Format:  In-person presentation to Conference participants
Information: https://web.cvent.com/event/285a8cb1-8583-4467-ac01-1bb790d0f3fd/websitePage:f6463205-0db9-4bdc-90c5-b5303d6a3fbe

All Events

Featured Presentations

Download

Chemomab Corporate Overview - November 2024